home / stock / aktx / aktx quote
Last: | $3.53 |
---|---|
Change Percent: | 0.55% |
Open: | $3.62 |
Close: | $3.53 |
High: | $3.87 |
Low: | $3.53 |
Volume: | 3,092 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.53 | $3.62 | $3.53 | $3.87 | $3.53 | 3,092 | 07-19-2024 |
$3.64 | $3.88 | $3.64 | $3.91 | $3.63 | 21,566 | 07-18-2024 |
$3.83 | $3.85 | $3.83 | $3.85 | $3.755 | 18,469 | 07-17-2024 |
$3.7001 | $3.66 | $3.7001 | $3.86 | $3.51 | 34,959 | 07-16-2024 |
$3.74 | $3.5 | $3.74 | $3.74 | $3.5 | 16,726 | 07-15-2024 |
$3.5 | $3.56 | $3.5 | $3.6402 | $3.29 | 26,460 | 07-12-2024 |
$3.5307 | $3.49 | $3.5307 | $3.729 | $3.3801 | 48,033 | 07-11-2024 |
$3.38 | $2.98 | $3.38 | $3.53 | $2.8701 | 42,718 | 07-10-2024 |
$2.81 | $2.84 | $2.81 | $2.98 | $2.68 | 8,630 | 07-09-2024 |
$2.88 | $2.84 | $2.88 | $3.03 | $2.84 | 5,717 | 07-08-2024 |
$2.87 | $3.18 | $2.87 | $3.18 | $2.8292 | 8,706 | 07-05-2024 |
$3.1818 | $3.23 | $3.1818 | $3.3066 | $3.1008 | 2,374 | 07-04-2024 |
$3.1818 | $3.23 | $3.1818 | $3.3066 | $3.1008 | 2,374 | 07-03-2024 |
$3.1 | $3.27 | $3.1 | $3.4 | $3.0401 | 23,783 | 07-02-2024 |
$3.215 | $2.85 | $3.215 | $3.63 | $2.85 | 26,381 | 07-01-2024 |
$2.7 | $2.7 | $2.7 | $2.7 | $2.61 | 12,396 | 06-28-2024 |
$2.63 | $2.66 | $2.63 | $3.11 | $2.62 | 17,980 | 06-27-2024 |
$2.72 | $2.89 | $2.72 | $3.1079 | $2.71 | 20,340 | 06-26-2024 |
$2.77 | $3.6 | $2.77 | $3.64 | $2.73 | 70,963 | 06-25-2024 |
$3.66 | $3.8 | $3.66 | $3.89 | $3.4914 | 23,288 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
Akari Therapeutics Plc Website:
Interim CEO employment contract consists solely of equity compensation Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotec...
BOSTON and LONDON, June 04, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, today announced the successful initial closing of a private placement financing round. This transaction is ...
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan fo...